Sana Biotechnology
Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients. We are a passionate group of people working together to create an enduring company that changes how the world treats disease. Sana has operations in Seattle, Cambridge, South San Francisco, and Rochester.
NEWS
Sana Biotechnology has filed with the U.S. Securities and Exchange Commission to raise up to $150 million in an initial public offering to help support the company’s cell-based therapy discovery and development operations.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
BioSpace is proud to present its NextGen Bio “Class of 2021,” a list of up-and-coming life science startups in North America that recently launched.
On October 30, the company announced the acquisition of long-time collaborator Oscine Corp.
Biopharma and life science companies from across the globe strengthen their leadership teams and boards with these Movers & Shakers.
JOBS
IN THE PRESS